TEZSPIRE^® (tezepelumab injection) is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma.

TEZSPIRE® is not indicated for relief of acute bronchospasm or status asthmaticus.

Please consult the TEZSPIRE^® Product Monograph at www.astrazeneca.ca/content/dam/az-ca/downloads/productinformation/tezspire-product-monograph-en.pdf or Click here for more information relating to:

• Relevant warnings and precautions regarding not using TEZSPIRE^® to treat acute symptoms or asthma exacerbations, reduction of corticosteroid dosage, risk of serious cardiac adverse events, parasitic (Helminth) infection, risk of serious infections, pregnancy, hypersensitivity reactions, and risk of anaphylaxis.
• Conditions of clinical use, adverse reactions, drug interactions and dosing instructions

The Product Monograph is also available by calling AstraZeneca Canada Inc. at 1-800-668-6000.